- Home
- INV vs FATE Comparison
INV vs FATE Comparison
Compare INV & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INV
- FATE
- Stock Information
- Founded
- INV 2015
- FATE 2007
- Country
- INV United States
- FATE United States
- Employees
- INV N/A
- FATE N/A
- Industry
- INV
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INV
- FATE Health Care
- Exchange
- INV NYSE
- FATE Nasdaq
- Market Cap
- INV 448.7M
- FATE 406.5M
- IPO Year
- INV N/A
- FATE 2013
- Fundamental
- Price
- INV $10.66
- FATE $2.07
- Analyst Decision
- INV
- FATE Hold
- Analyst Count
- INV 0
- FATE 10
- Target Price
- INV N/A
- FATE $6.75
- AVG Volume (30 Days)
- INV 19.2K
- FATE 3.0M
- Earning Date
- INV 11-14-2024
- FATE 11-12-2024
- Dividend Yield
- INV N/A
- FATE N/A
- EPS Growth
- INV N/A
- FATE N/A
- EPS
- INV N/A
- FATE N/A
- Revenue
- INV $988,000.00
- FATE $13,447,000.00
- Revenue This Year
- INV N/A
- FATE N/A
- Revenue Next Year
- INV N/A
- FATE N/A
- P/E Ratio
- INV N/A
- FATE N/A
- Revenue Growth
- INV 4.88
- FATE N/A
- 52 Week Low
- INV $8.55
- FATE $1.96
- 52 Week High
- INV $18.75
- FATE $8.83
- Technical
- Relative Strength Index (RSI)
- INV N/A
- FATE 36.05
- Support Level
- INV N/A
- FATE $1.96
- Resistance Level
- INV N/A
- FATE $2.35
- Average True Range (ATR)
- INV 0.00
- FATE 0.34
- MACD
- INV 0.00
- FATE -0.01
- Stochastic Oscillator
- INV 0.00
- FATE 7.14
About INV INNVENTURE INC
Innventure Inc creates, funds, operates, and rapidly scales companies in strategic collaboration with MNCs. It provides company creation, corporate strategy, technology optimization, operations, commercialization, and funding. Innventure analyzes the market, including proprietary data provided by MNCs, to identify where their well-protected, breakthrough technologies address market needs and have the potential to create $1B+ in new enterprise value.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.